NSC Global Limited
3rd Floor, West Building
1 London Bridge London
SE1 9BG
Who we are
Work with us
© Copyright 2020 NSC Global Ltd.
Our people
All our people have a drive to solve problems; an ambition to make clients happy and a determination to succeed where others have failed.
We’ll be anywhere you need us to be, fast, and we’ll always get the job done.
Yaseen Khan
Chief Executive Officer
Yaseen founded NSC in 1997 based on one simple principle: big companies need someone they can trust to manage their global IT, so they don’t have to. Someone who’s not afraid to roll up their sleeves and get stuck in to deliver a real commercial advantage.
Now overseeing the business in his role as CEO, Yaseen ensures everything about us embodies his expert, agile and entrepreneurial spirit.
Sascha Groeger
Chief Commercial Officer
After graduating from European Business School, Sascha entered Corporate Finance where he successfully led several technology companies to IPO.
Having spent the last 15 years in senior IT Management positions, Sascha now leads our sales operations, marketing and business strategy from across the pond in the US.
More about us
Who are we – the key facts
All our people have a drive to solve problems; an ambition to make clients happy and a determination to succeed where others have failed.
We’ll be anywhere you need us to be, fast, and we’ll always get the job done.
PRIVATELY OWNED AND FUNDED
Multinational Company – London HQ.
FOUNDED IN 1997 –
23 years in business.
$300 MILLION
In revenue with strong profit growth.
LOCAL PRESENCE IN
34 entities, operating in 180 countries.
2500+
NSC employees.
GLOBAL
Warehousing, storage facilities, logistics and staging facilities in 67 locations.
24 x 7 x 365
Service centres in UK, USA, Hungary and South Africa.
90+ ACCREDITED
Field service partners providing more than 12,000 engineering resources around the world.
SUPPORTED
By 20 leading tech OEMs.
We support
A range of charities
As part of our goal to always do more and always go further, we try to do our bit with a number of different charities to help those who are really in need.
THE OPEN UNIVERSITY OPENLEARN
At NSC we are proud to support a number of charities, and our partnership with OpenLearn embodies our fundamental belief that equal educational opportunities should be available to everyone. Education is a privilege many of us take for granted, but sadly access to learning is not always as accessible as it should be.
NSC has partnered with The Open University and OpenLearn, to provide free courses and training to anyone looking to change their career path or expand their skills and the job opportunities available to them.
2020 has seen the world change dramatically, and the technology sector has been crucial in helping organisations and individuals stay connected, enabling employees to work remotely and keep their businesses running efficiently. At NSC we believe that an understanding of technology is more important than ever for anyone entering, or already part of the business world.
OpenLearn is home to a large range of technology courses which allow individuals to enhance their understanding of all aspects of technology, from very specific specialist training for IT professionals to broader more general courses for those looking to gain an insight into the industry.
To find out more about the courses we recommend for those looking to expand their technology skills and understanding of this critical and fast-growing sector please click here.
THE PRINCE’S TRUST
We believe in aiding towards a bright future for young people. Last year we advised young entrepreneurs and awarded seed funding to their promising start ups, helping educate 20 young people on starting and running a business. Fourteen keen cyclists at NSC in London also helped to raise money for The Prince’s Trust by taking part in the Palace to Palace cycle ride.
LEUKAEMIA & LYMPHOMA SOCIETY
With our support LLS was able to develop an innovative new chemotherapy drug for patients with Acute Myeloid Leukaemia – one of the most difficult to treat blood cancers.
With an efficiency rate close to three times that of similar treatments, this breakthrough drug is saving lives.